Trial Profile
A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PIL
- 30 Jan 2024 Status changed from recruiting to discontinued (due to poor accrual).
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 New trial record